FibroBiologics (FBLG) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $7.00 price target on the stock.
FibroBiologics, Inc. (FBLG)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
FBLG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FBLG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FBLG alerts
High impacting FibroBiologics, Inc. news events
Weekly update
A roundup of the hottest topics
FBLG
News
- FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid TechnologyGlobeNewswire
- FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot UlcersGlobeNewswire
- FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of OsteoporosisGlobeNewswire
- FibroBiologics to Present at the BIO Investment & Growth SummitGlobeNewswire
- FibroBiologics (FBLG) had its "buy" rating reaffirmed by HC Wainwright.MarketBeat
FBLG
Earnings
- 5/14/25 - Miss
FBLG
Analyst Actions
- 2/26/26 - HC Wainwright
FBLG
Sec Filings
- 3/13/26 - Form 10-K/A
- 3/6/26 - Form 8-K
- 3/5/26 - Form 4
- FBLG's page on the SEC website